Drug Development Infrastructure Supporting the Research Community in Medication Repurposing for Substance Use Disorders
UpcomingNational Institutes of Health · Opportunity number RFA-DA-28-009 · Forecast
Eligibility
Nonprofits are listed as eligible applicants.
- County governments
- Small businesses
- State governments
- City or township governments
- Special district governments
- Private institutions of higher education
- Public housing authorities/Indian housing authorities
- Independent school districts
- Public and state controlled institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Native American tribal governments (Federally recognized)
- For profit organizations other than small businesses
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Description
The National Institute on Drug Abuse (NIDA) seeks to advance its mission by supporting a dynamic and adaptable drug-development infrastructure to accelerate medication repurposing and repositioning for substance use disorders (SUDs). The infrastructure will serve academic and biotech investigators by providing coordinated scientific expertise, shared resources, and tailored support across the drug-development continuum. Capabilities may include in silico discovery, target and assay validation, preclinical and translational development, pharmacology, toxicology, clinical protocol development, patient engagement, Target Product Profile development, Freedom-to-Operate and intellectual property strategy, regulatory guidance, and market-access planning. The infrastructure will also engage the research community through outreach, proposal solicitation, and a structured project-selection process, supporting user-led projects across a broad range of SUD indications. The goal is to help promising repurposed and repositioned therapeutics progress toward clinical development and potential market access. Grant authorities that allow the NIDA to forecast this opportunity are as follows: 42 U.S.C. 241 and 284.
Funding
| Total program funding | $2,500,000 |
|---|---|
| Award floor | Not listed |
| Award ceiling | Not listed |
| Category | Health |
| Assistance listing | 93.DA5 |
Official sources
Related federal opportunities
- Early Immune System Development and Ontogeny (R01 Clinical Trial Optional) National Institutes of Health · PAR-25-362 · closes Nov 5, 2028
- Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional) National Institutes of Health · PAR-28-014 · closes Oct 11, 2029
- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) National Institutes of Health · RFA-CA-27-019 · closes Oct 19, 2027
- Early-Stage Dissemination and Implementation Research in Communication Disorders (R21 Clinical Trial Optional) National Institutes of Health · RFA-DC-26-001 · closes Jun 17, 2027
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) National Institutes of Health · RFA-CA-28-001 · closes Jun 4, 2027
- Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required) National Institutes of Health · PAR-25-183 · closes Oct 15, 2027
- Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required) National Institutes of Health · PAR-25-184 · closes Oct 15, 2027
- Early to Definitive Clinical Trials (R61/R33 Clinical Trial Required) National Institutes of Health · PAR-28-074 · closes Jul 31, 2027
All National Institutes of Health opportunities open to nonprofits · All federal grants by agency
Last verified on Grants.gov Nov 11, 2026. Grantvello is not affiliated with Grants.gov or National Institutes of Health. The notice on Grants.gov is the binding text.